What happened with BAX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Baxter International supplies products that healthcare providers use to give fluids and medicines, perform surgery and care for patients. Its largest revenue segment covers IV solutions, infusion equipment, intravenous nutrition and surgical products such as materials that stop bleeding. Smart beds and patient-monitoring equipment form another substantial business, alongside injectable medicines, inhaled anesthetics and drug-compounding services. Baxter has sold its Kidney Care business.
Hospitals and other care facilities buy directly from Baxter or through distributors and other intermediaries. Some contracts combine equipment delivered upfront with consumables supplied over time. In the United States, group purchasing organizations negotiate prices for member hospitals, so access to these agreements matters to sales. Some multiyear contracts limit price increases. Baxter also relies on Cardinal Health, Medline and other third parties to warehouse and ship a significant share of its U.S. products.
Selling most products requires Baxter to obtain and maintain regulatory approvals in each market. Its Novum LVP infusion pumps remain under a voluntary distribution and installation hold in the United States and Canada, except for medical necessity; Spectrum IQ pumps remain available as an alternative.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Baxter’s results also depend on infusion competition with privately held B. Braun and on manufacturing and transition obligations to its former Kidney Care business, now Vantive.
ICU Medical competes directly with Baxter for hospitals’ and alternate-care facilities’ purchases of infusion pumps, IV sets, connectors and IV solutions. Watch its pump business: ICU Medical says pumps can help it sell more higher-margin infusion consumables, extending the competition beyond equipment.
BD competes with Baxter for hospital purchases of infusion pumps, medication-delivery products and IV consumables—the same equipment and supplies hospitals buy to deliver medicines to patients.
GE HealthCare competes with Baxter for hospitals’ patient-monitoring and electrocardiogram (ECG) equipment purchases, putting both companies in contention for the tools hospitals use to track patients and record heart activity.
Philips competes with Baxter for hospitals’ connected patient-monitoring and electrocardiogram (ECG) technologies, overlapping in the systems hospitals buy to connect patient monitoring and diagnose heart activity.
Medtronic competes with Baxter for hospitals’ purchases of surgical equipment, respiratory technologies and patient-monitoring systems, overlapping across several types of hospital equipment rather than infusion alone.
Medline Inc.’s own-brand hospital supplies and Baxter’s essential consumables both depend on recurring purchases by care providers; Medline also warehouses and ships Baxter products in the United States. Watch Medline Brand sales for a read on purchasing of everyday medical-surgical supplies.
Solventum’s MedSurg supplies and Baxter’s infusion and surgical consumables depend on the same recurring hospital purchasing and patient-care activity. Watch Solventum’s MedSurg sales, which include wound dressings, IV-site management and surgical supplies, rather than its dental or software businesses.
Johnson & Johnson competes with Baxter through Ethicon products used to stop bleeding and seal tissue during surgery—hemostats and sealants that overlap with Baxter’s advanced-surgery range.
Pfizer competes with Baxter in injectable medicines for hospitals: its sterile-injectable portfolio overlaps with Baxter’s specialty injectable pharmaceuticals.
Teleflex competes with Baxter for hospitals’ purchases of infusion-related consumables and anesthesia products, selling supplies used in delivering infusions and providing anesthesia.
CONMED Corporation competes with Baxter for hospital operating-room purchases of surgical visualization systems and powered surgical equipment—the tools used to view the surgical field and operate powered instruments.
Baxter International Inc. earningsThis company
Baxter’s report will show whether infusion pumps and IV solutions are recovering from shipment and installation holds and weaker U.S. demand, helping its core medical-products business grow.
Read Infusion Therapies & Technologies sales alongside U.S. IV-solutions demand, and check whether Novum LVP pump shipments and installations have resumed. Rising sales with resumed deliveries would show that hospital demand and Baxter’s ability to supply are improving; weak sales or continued restrictions would show those pressures still outweigh pricing and cost reductions.
ICU Medical Inc earningsICUI
ICU Medical’s report will show whether hospitals and other care sites are buying its infusion pumps and related consumables, a market where it competes directly with Baxter.
Read ICU Medical’s pump business alongside its infusion-consumables sales. Stronger pumps with growing consumables would show equipment purchases pulling through recurring supplies, increasing competition for Baxter in both; weakness in both would show limited momentum for this rival in their shared market, not guarantee higher Baxter sales.
